E!115900 PREVAIL, 3H Biomedical AB, Preclinical development of novel ERRalpha inhibitors for treatment of Triple Negative Breast Cancer
| Reference number | |
| Coordinator | 3H Biomedical AB |
| Funding from Vinnova | SEK 4 490 820 |
| Project duration | October 2017 - August 2021 |
| Status | Completed |
| Venture | Eurostars |
Important results from the project
The goal of the PREVAIL project is to develop a new targeted therapeutic treatment for triple-negative breast (TNBC). A promising drug candidate that has been verified in a series of preclinical safety and efficacy experiments has gone to clinical trials.
Expected long term effects
The PREVAIL project has sucessfully delivered a candidate drug to treat TNBC with associated safety and efficacy data packages. The candidate drug is currently in clinical trials and commercialization in the global market. This will generate income from upfront, milestone and royalty payments. Marketing and sales of patient-derived TNBC cell model, TNBC cancer stem cells and Tamoxifen and Doxorubicin drug-resistant TNBC cell lines are ready after two months completion of the project and those products will generate income for 3H Biomedical AB.
Approach and implementation
Preclinical safety and efficacy experiments have been performed to identify therapeutic breast cancer treatment candidates based on estrogen-related receptor alpha inhibitors. By conducting translational studies early in the drug development process, safety and efficacy of new drug substances can be obtained earlier, leading to lower costs.